---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-012128"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:23:58.922097+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch

## Summary
- Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.
- FY 2023 revenue $19.0M (incl. $10M Viatris milestone) vs $39.9M in 2022; net loss $10.0M ($0.46/share) vs net income $17.9M in 2022.
- APX3330 SPA submitted for Phase 3 registrational trial in diabetic retinopathy; FDA agreed on primary endpoint.
- RYZUMVI (phentolamine) approved Sep 2023; launch expected H1 2024; Viatris to fund further development for presbyopia and post-refractive surgery.
- Leadership changes: George Magrath CEO (Nov 2023), new CFO and CSDO appointed Feb 2024.

## SEC filing metadata
- accession: 0001140361-24-012128
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/0001140361-24-012128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/ef20023531_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-012128
- JSON: https://secwatch.observer/filing/0001140361-24-012128.json
- Plain text: https://secwatch.observer/filing/0001140361-24-012128.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively
  - Result: reported results
  source text: On March 8, 2024, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036124012128/0001140361-24-012128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.